Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia-implications for immunotherapy

Clinical Cancer Research

Volumn 19, Issue 18, 2013, Pages 5079-5091

  Weber, Gerrit ^a,b,d,e   Caruana, Ignazio ^a,b,d,e   Rouce, Rayne H ^b,e,f   Barrett, A John ^g   Gerdemann, Ulrike ^a,b,d,e   Leen, Ann M ^a,b,d,e   Rabin, Karen R ^b,e,f   Bollard, Catherine M ^a,b,c,d,e  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b Department of Pediatrics ^*  (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d HOUSTON METHODIST HOSPITAL   (United States)

^e TEXAS CHILDREN S HOSPITAL   (United States)

^f TEXAS CHILDREN S CANCER CENTER   (United States)

^g NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN 3; PRAME ANTIGEN; SURVIVIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE TRANSFER; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL EXPANSION; CHILD; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; CHILD; COLONY-FORMING UNITS ASSAY; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; HLA-A2 ANTIGEN; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; INHIBITOR OF APOPTOSIS PROTEINS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; WT1 PROTEINS;

EID: 84884573470     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0955     Document Type: Article

References (50)

1. Kennedy-Nasser AA, Bollard CM, Myers GD, Leung KS, Gottschalk S, Zhang Y, et al. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant 2008;14:1245-52.
2. Eapen M, Zhang MJ, Devidas M, Raetz E, Barredo JC, Ritchey AK, et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with acute lymphoblastic leukemia in a second remission after an isolated central nervous system relapse: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. Leukemia 2008;22:281-6.
3. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-50.
4. Porter DL, Orloff GJ, Antin JH. Donor mononuclear cell infusions as therapy for B-cell lymphoproliferative disorder following allogeneic bone marrow transplant. Transplant Sci 1994;4:12-4.
5. Rabin KR, Gramatges MM, Borowitz MJ, Palla SL, Shi X, Margolin JF, et al. Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2012;59:468-74.
6. Rezvani K, Yong AS, Tawab A, Jafarpour B, Eniafe R, Mielke S, et al. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 2009;113:2245-55.
7. Choi SJ, Lee JH, Lee JH, Kim S, Lee YS, Seol M, et al. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study. Bone Marrow Transplant 2005;36:163-9.
8. Levine JE, Barrett AJ, Zhang MJ, Arora M, Pulsipher MA, Bunin N, et al. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplant 2008;42:201-5.
9. Collins RH Jr, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W, et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000;26:511-6.
10. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimericantigenreceptor-transduced T cells. Blood 2012;119:2709-20.
11. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011;121:1822-6.
12. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509-18.
13. Rezvani K, Price DA, Brenchley JM, Kilical Y, Gostick E, Sconocchia G, et al. Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity. Cytotherapy 2007;9:245-51.
14. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008;111:236-42.
15. Weber G, Gerdemann U, Caruana I, Savoldo B, Hensel NF, Rabin KR, et al. Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. Leukemia 2013;27:1538-47.
16. Boublikova L, Kalinova M, Ryan J, Quinn F, O'Marcaigh A, Smith O, et al. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 2006;20:254-63.
17. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.
18. Esh AM, Atfy M, Azizi NA, El Naggar MM, Khalil EE, Sherief L. Prognostic significance of survivin in pediatric acute lymphoblastic leukemia. Indian J Hematol Blood Transfus 2011;27:18-25.
19. Martinez A, Olarte I, Mergold MA, Gutierrez M, Rozen E, Collazo J, et al. mRNA expression of MAGE-A3 gene in leukemia cells. Leuk Res 2007;31:33-7.
20. Steinbach D, Viehmann S, Zintl F, Gruhn B. PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet 2002;138:89-91.
21. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24.
22. Gerdemann U, Katari U, Christin AS, Cruz CR, Tripic T, Rousseau A, et al. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma. Mol Ther 2011;19:2258-68.
23. Weber G, Karbach J, Kuci S, Kreyenberg H, Willasch A, Koscielniak E, et al. WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation. Leukemia 2009;23:1634-42.
24. Doubrovina E, Carpenter T, Pankov D, Selvakumar A, Hasan A, O'Reilly RJ. Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1 (+) leukemias. Blood 2012;120:1633-46.
25. Kobayashi H, Nagato T, Aoki N, Sato K, Kimura S, Tateno M, et al. DefiningMHCclass II T helper epitopes for WT1 tumor antigen. Cancer Immunol Immunother 2006;55:850-60.
26. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8 (+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000;95:286-93.
27. Rezvani K, Brenchley JM, Price DA, Kilical Y, Gostick E, Sewell AK, et al. T-cell responses directed against multiple HLA-A 0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res 2005;11(24 Pt 1):8799-807.
28. Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M, et al. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 2007;110:201-10.
29. Kern F, Surel IP, Faulhaber N, Frommel C, Schneider-Mergener J, Schonemann C, et al. Target structures of the CD8 (+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol 1999;73:8179-84.
30. Vera JF, Brenner LJ, Gerdemann U, Ngo MC, Sili U, Liu H, et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother 2010;33:305-15.
31. Hinrichs CS, Borman ZA, Cassard L, Gattinoni L, Spolski R, Yu Z, et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A 2009;106:17469-74.
32. Hinrichs CS, Borman ZA, Gattinoni L, Yu Z, Burns WR, Huang J, et al. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 2011;117:808-14.
33. Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009;114:1958-67.
34. Quintarelli C, Dotti G, De AB, Hoyos V, Mims M, Luciano L, et al. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 2008;112:1876-85.
35. Rezvani K, Yong AS, Mielke S, Savani BN, Jafarpour B, Eniafe R, et al. Lymphodepletion is permissive to the development of spontaneous Tcell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy. Cancer Immunol Immunother 2012;61:1125-36.
36. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010;115:925-35.
37. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006;12:1160-6.
38. Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique S, McSkeane T, Ryan G, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010;116:1908-18.
39. Bhatla T, Wang J, Morrison DJ, Raetz EA, Burke MJ, Brown P, et al. Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood 2012;119:5201-10.
40. Cruz CR, Gerdemann U, Leen AM, Shafer JA, Ku S, Tzou B, et al. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res 2011;17:7058-66.
41. Handgretinger R, Zugmaier G, Henze G, Kreyenberg H, Lang P, von SA. Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia. Leukemia 2011;25:181-4.
42. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in Blineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29:2493-8.
43. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009;113:6541-8.
44. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4 (+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-68.
45. Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW, et al. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol 2000;165:6047-55.
46. Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010;116:171-9.
47. Guo Y, Niiya H, Azuma T, Uchida N, Yakushijin Y, Sakai I, et al. Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner. Blood 2005;106:1415-8.
48. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005;54:721-8.
49. Gao L, Bellantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM, et al. Selective elimination of leukemic CD34 (+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000;95:2198-203.
50. Asemissen AM, Keilholz U, Tenzer S, Muller M, Walter S, Stevanovic S, et al. Identification of a highly immunogenic HLA-A 01-binding T cell epitope of WT1. Clin Cancer Res 2006;12:7476-82.